Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoang–Xuan, K.
Right arrow Articles by Sanson, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoang–Xuan, K.
Right arrow Articles by Sanson, M.
Related Collections
Right arrow All Oncology
Right arrow Primary brain tumor
Right arrow All Genetics
Neurology 2001;57:1278-1281
© 2001 American Academy of Neurology
Articles

Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression

K. Hoang–Xuan, MD, J. He, MD PhD;, S. Huguet, MSc, K. Mokhtari, MD, Y. Marie, MSc, M. Kujas, MD, P. Leuraud, MSc, L. Capelle, MD, J. Y. Delattre, MD, J. Poirier, MD, P. Broët, MD PhD and M. Sanson, MD PhD

From the Biologie des interactions neurone-glie (Drs. Hoang–|DNXuan, He, Delattre, and Sanson, and S. Huguet, Y. Marie, and P. Leuraud), INSERM U495 et Université P. et M. Curie, Federation Neurologique Mazarin (Drs. Hoang-Xuan, Delattre, and Sanson), Laboratoire de Neuropathologie R. Escourolle (Dr. Mokhtari), Laboratoire d’Histologie-Embryologie et de Cytogénétique (Drs. Kujas, Poirier, and Sanson), and Service de Neurochirurgie (L. Capelle), Groupe hospitalier Pitié-Salpêtrière, Paris; and Unité de Biostatistique (Dr. Broët), INSERM U472, Hôpital Paul Brousse, Villejuif, France.

Address correspondence and reprint requests to Dr. Khê Hoang-Xuan, Fédération Neurologique Mazarin, Groupe hospitalier Pitié-Salpêtrière, 47 Bld de l’hôpital, 75651 Paris Cedex 13, France; e-mail: khe.hoang-xuan{at}psl.ap-hop-paris.fr

Objective: To identify different genetic molecular profiles in oligodendrogliomas and to evaluate their prognostic significance. Methods: The main genetic alterations reported in glial tumors were investigated in 26 oligodendrogliomas (10 World Health Organization grade II and 16 World Health Organization grade III). Correlation between identified molecular changes and pathologic grade or clinical course was subsequently analyzed using univariate and multivariate statistical analyses. Results: Loss of heterozygosity (LOH) on chromosome 1p, 19q, and 10; P16/CDKN2A homozygous deletion; EGFR (epidermal growth factor receptor) amplification; and TP53 and PTEN mutations were observed in 14 (54%), 15 (58%), 9 (35%), 7 (27%), 5 (19%), 1 (4%), and 0 cases. LOH 1p and 19q were tightly associated (p < 0.0001). A mutual exclusion was found between LOH 1p/19q and EGFR amplification (p = 0.01), P16/CDKN2A deletions (p = 0.001), or LOH on 10q (p = 0.03), suggesting the existence of distinct genetic subsets in oligodendrogliomas. On univariate analysis, age <50 years (p = 0.002) and LOH 1p (p = 0.01) were associated with a longer progression-free survival (PFS) whereas LOH 10q (p = 0.03) and EGFR amplification (p = 0.007) were associated with a worse PFS. In multivariate analyses, age <50 years (p = 0.001) and LOH 1p (p = 0.006) remained independent predictive factors for PFS. Conclusion: These results provide evidence for two alternative molecular pathways of progression in oligodendrogliomas. The first one is associated with loss of 1p and 19q and the second one with P16/CDKN2A deletion, 10q loss, and EGFR amplification. The findings confirm the value of loss of 1p as predictor of longer progression-free survival; in addition, the study demonstrates the unfavorable impact of 10q loss and EGFR amplification on the prognosis.




This article has been cited by other articles:


Home page
 Am J Clin PatholHome page
D. Mahajan and R. A. Prayson
Repeated Molecular Testing in Gliomas: A Retrospective Study of 53 Cases
Am J Clin Pathol, July 1, 2009; 132(1): 118 - 124.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. P. Mason and J. G. Cairncross
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
Neurology, July 29, 2008; 71(5): 365 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
L. E. Abrey, D. N. Louis, N. Paleologos, A. B. Lassman, J. J. Raizer, W. Mason, J. Finlay, D. R. MacDonald, L. M. DeAngelis, J. G. Cairncross, et al.
Survey of treatment recommendations for anaplastic oligodendroglioma
Neuro-oncol, July 1, 2007; 9(3): 314 - 318.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. Kaloshi, A. Benouaich-Amiel, F. Diakite, S. Taillibert, J. Lejeune, F. Laigle-Donadey, M.-A Renard, W. Iraqi, A. Idbaih, S. Paris, et al.
Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome
Neurology, May 22, 2007; 68(21): 1831 - 1836.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Walker, B. Haylock, D. Husband, K. A. Joyce, D. Fildes, M. D. Jenkinson, T. Smith, J. Broome, D. G. du Plessis, and P. C. Warnke
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors
Neurology, June 13, 2006; 66(11): 1661 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. J. French, S. M.A. Swagemakers, J. H.A. Nagel, M. C.M. Kouwenhoven, E. Brouwer, P. van der Spek, T. M. Luider, J. M. Kros, M. J. van den Bent, and P. A. Sillevis Smitt
Gene Expression Profiles Associated with Treatment Response in Oligodendrogliomas
Cancer Res., December 15, 2005; 65(24): 11335 - 11344.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
K. K. Koeller and E. J. Rushing
From the Archives of the AFIP: Oligodendroglioma and Its Variants: Radiologic-Pathologic Correlation
RadioGraphics, November 1, 2005; 25(6): 1669 - 1688.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
F. Laigle-Donadey, N. Martin-Duverneuil, J. Lejeune, E. Criniere, L. Capelle, H. Duffau, P. Cornu, P. Broet, M. Kujas, K. Mokhtari, et al.
Correlations between molecular profile and radiologic pattern in oligodendroglial tumors
Neurology, December 28, 2004; 63(12): 2360 - 2362.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Hoang-Xuan, L. Capelle, M. Kujas, S. Taillibert, H. Duffau, J. Lejeune, M. Polivka, E. Criniere, Y. Marie, K. Mokhtari, et al.
Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions
J. Clin. Oncol., August 1, 2004; 22(15): 3133 - 3138.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Sanson, S. Cartalat-Carel, S. Taillibert, M. Napolitano, L. Djafari, J. Cougnard, H. Gervais, F. Laigle, A. Carpentier, K. Mokhtari, et al.
Initial chemotherapy in gliomatosis cerebri
Neurology, July 27, 2004; 63(2): 270 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Leuraud, L. Taillandier, J. Medioni, L. Aguirre-Cruz, E. Criniere, Y. Marie, M. Kujas, J.-L. Golmard, A. Duprez, J.-Y. Delattre, et al.
Distinct Responses of Xenografted Gliomas to Different Alkylating Agents Are Related to Histology and Genetic Alterations
Cancer Res., July 1, 2004; 64(13): 4648 - 4653.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Walker, D. G. du Plessis, K. A. Joyce, Y. Machell, J. Thomson-Hehir, S. A. Al Haddad, J. C. Broome, and P. C. Warnke
Phenotype versus Genotype in Gliomas Displaying Inter- or Intratumoral Histological Heterogeneity
Clin. Cancer Res., October 15, 2003; 9(13): 4841 - 4851.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. van den Bent, O.-L. Chinot, and J. G. Cairncross
Recent developments in the molecular characterization and treatment of oligodendroglial tumors
Neuro-oncol, April 1, 2003; 5(2): 128 - 138.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
H. Ding, P. Shannon, N. Lau, X. Wu, L. Roncari, R. L. Baldwin, H. Takebayashi, A. Nagy, D. H. Gutmann, and A. Guha
Oligodendrogliomas Result from the Expression of an Activated Mutant Epidermal Growth Factor Receptor in a RAS Transgenic Mouse Astrocytoma Model
Cancer Res., March 1, 2003; 63(5): 1106 - 1113.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.